A new weapon against Parkinson’s-related psychosis
December 16, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Parkinson's disease, cannabidiol, cannabis, feature, pharma
Dr Arthur Roach, Director of Research at the charity Parkinson’s UK, discusses new trials on cannabidiol in the treatment of …
Transgene ceases development of failed advanced non-squamous non-small cell lung cancer immunotherapy candidate
December 16, 2019Research and Development, Sales and Marketing Cancer, Transgene, lung cancer, pharma
Cancer immunotherapeutics firm Transgene has confirmed that it is to terminate further development of its TG4010 candidate in the first-line …
Novartis pulls fevipiprant development in asthma following trial failure
December 16, 2019Research and Development, Sales and Marketing Fevipiprant, Novartis, asthma, pharma, trial failure
Novartis has made it known that its DP2 receptor antagonist fevipiprant failed at Phase 3 to show clinically relevant levels …
NICE reverses previous decision to recommend Vifor Pharma’s Veltassa for NHS treatment of hyperkalaemia
December 16, 2019Sales and Marketing NHS, NICE, Veltassa, Vifor pharma
It has emerged that NICE has awarded its recommendation to Vifor Pharma’s Veltassa (patiromer) for treating hyperkalaemia, a condition classified …
Biogen terminates gosuranemab in progressive surpanuclear palsy following Phase 2 failure
December 16, 2019Research and Development, Sales and Marketing Biogen, pharma, trial failure
Biogen has revealed its intention to shut down further development of gosuranemab after results of a Phase 2 study showed …
Pfizer’s Vyndaqel scores CHMP support for transthyretin amyloidosis in cardiomyopathy patients
December 16, 2019Sales and Marketing Pfizer, Vyndaqel, pharma
Pfizer’s once-daily 61mg oral capsule formulation of Vyndaqel (tafamidis) has secured a positive opinion from the European Medicines Agency’s (EMA) …
Genmab’s Darzalex secures CHMP recommendation in Europe for front-line multiple myeloma
December 13, 2019Medical Communications, Sales and Marketing CHMP, Genmab, darzalex, pharma
The Committee for Medicinal Products for Human Use (CHMP), an advisory panel for the European Medicines Agency, has given its …
Top Ten most popular articles on Pharmafile.com this week
December 13, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing pharma, top ten
As the UK reels from the news that Boris Johnson and the Conservative Party have stormed the general election and …
Novartis’ Beovu scores CHMP recommendation after proving non-inferior to Eylea in wet age-related macular degeneration
December 13, 2019Medical Communications, Sales and Marketing Beovu, EMA, Novartis, pharma
Novartis’ single-chain antibody fragment Beovu has secured recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use …
FDA U-turns to approve Sarepta’s Vyondys 53 in Duchenne muscular dystrophy
December 13, 2019Medical Communications, Sales and Marketing FDA, Vyondys 53, pharma, sarepta
The FDA has surprised industry pundits by choosing to approve Sarepta’s Vyondys 53 under an accelerated pathway for the treatment …
Novartis Kisqali shows superior survival rates to AstraZeneca’s Faslodex in advanced breast cancer
December 12, 2019Business Services Journal of Medicine, Novartis, menopause
Novartis Kisqali (ribociclib) plus fulvestrant demonstrated a statistically significant improvement in overall survival rates, with an almost 30% reduction in …
Roche’s subcutaneous Perjeta/Herceptin combo proves non-inferior to IV formulation in HER2-positive early breast cancer
December 12, 2019Research and Development Cancer, Herceptin, Perjeta, Roche, breast cancer, pharma
New Phase 3 data from Roche has shown that its subcutaneously-delivered formulation of Perjeta (pertuzumab) and Herceptin (trastuzumab), in combination …
Election Day 2019: Where do the two frontrunners stand on the NHS?
December 12, 2019Business Services Boris, Boris Johnson, Corbyn NHS, Donald Trump, Jeremy Corbyn, NHS
The UK goes to the polls today, for the fourth election of the decade and the third since 2015.Despite the …
Shionogi’s Mulpleo recommended for NHS use across England, Wales and Scotland for chronic liver disease
December 12, 2019Sales and Marketing England, Mulpleo, NICE, Scotland, Scottish Medicines Consortium, Shionogi, Wales
Both the regulators governing NHS use of medicines in England, Wales and Scotland – the National Institute for Health and …
China approves AstraZeneca’s Imfinzi for advanced non-small cell lung cancer
December 12, 2019Sales and Marketing AstraZeneca, Imfinzi, pharma
AstraZeneca’s Imfinzi (durvalumab) is set to be made available in China after the country’s National Medical Products Administration (NMPA) decided …
New NAFTA terms put hold on Canadian drug prices
December 11, 2019Research and Development, Sales and Marketing Canada, NAFTA, US, pharma
NAFTA members have agreed to remove a provision that would have increased protections on biologics drugs. This means Canada, despite …
Multiple sclerosis market to be worth $32.9bn in 2028
December 11, 2019Research and Development Big Pharma, MS, MS treatement, multiple sclerosis, pharma
The multiple sclerosis (MS) market is expected to see a growth in sales, and increase from $19.8 billion in 2018 …
Correvio’s atrial fibrillation drug voted down by FDA committee over safety concerns
December 11, 2019Research and Development, Sales and Marketing Correvio Pharma, FDA, atrial fibrillation, pharma
It has emerged that Correvio Pharma’s anti-arrhythmic therapy Brinavess was shot down by the FDA’s Cardiovascular and Renal Drugs Advisory …
27,000 chickens to be culled after UK bird flu outbreak
December 11, 2019Research and Development Bird Flu, Chicken Flu, Swin Flu, influenza, influenza b
A chicken farm in Suffolk has been confirmed by the British government to have cases of bird flu. 27,000 birds …
Bristol-Myers Squibb drug boasts strong overall survival in acute myeloid leukaemia
December 11, 2019Research and Development ASH 19, Bristol-Myers Squibb, acute myeloid leukaemia, pharma
Bristol-Myers Squibb took the opportunity at the 2019 American Society of Hematology (ASH) Annual Meeting to reveal new efficacy data …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
